Asthma in Numbers

How many people live with asthma, how many of them actually receive treatment, and when should the numbers set off alarm bells? This article helps you read asthma data without getting confused between different sources. Different numbers are not necessarily a mistake, but it is also wrong to assume from the start that they can all be compared. To understand them, you need to ask who was counted, at what age, in which country, in which year and by which definition.

In brief: what is important to understand from the numbers?

Asthma is one of the most common chronic diseases in the world. According to the World Health Organization, about 363 million people were living with asthma in 2023, and it caused about 442,000 deaths. According to the GINA 2026 report, an estimated 300 million people have asthma, and there are about 1,000 deaths a day. The two estimates should not be combined into a single range: they are based on different sources and different data periods.

In Israel, there are several ways to identify asthma in the data: self-reports of a doctor's diagnosis, a diagnosis found in a medical record, or a quality indicator that identifies persistent asthma based on medication purchase criteria, and, in some inclusion pathways, also based on diagnoses recorded at doctor visits. Each one measures something different, so you cannot subtract one from another to determine how many people are undiagnosed or how many of those diagnosed are untreated.

There is also encouraging data: the rate of children's hospital admissions for asthma in Israel fell between 1996 and 2017. At the same time, data from the national survey, the quality indicators and an Israeli study on severe asthma published in 2017 raise questions about treatment and follow-up, but on their own they do not show how much treatment is lacking today.

“A number about asthma is never just a number. You need to know who was counted, how they were counted, and over what period.”

How Many People Worldwide Live with Asthma?

In April 2026, the World Health Organization published an estimate that about 363 million people worldwide were living with asthma in 2023, and about 442,000 people died from it. According to the same source, most asthma deaths occur in low-income or lower-middle-income countries, where underdiagnosis and undertreatment are still common.

GINA, the international guidelines body for asthma, uses a different estimate in its 2026 report: about 300 million people with asthma and about 1,000 deaths a day. GINA stresses that most of these deaths are preventable.

The gap between the estimates does not mean that one of the sources is necessarily wrong. It is a reminder that global data can vary depending on the information source and the data period. That is why each number should be used together with its context, and not presented as a single, absolute figure.

Why Are There Several Different Numbers for Asthma in Israel?

According to the Ministry of Health's INHIS-4 national health survey, conducted from 2018 to 2020, 8.5% of adults aged 21 and over in Israel reported that a doctor had diagnosed them with asthma at some point. The rate was 9.4% among men and 7.6% among women.

In the previous survey, conducted from 2013 to 2015, the rate was 7.4%. It is tempting to read this as an increase, but the comparison needs care: the later survey also included mobile phones, following a change introduced in the center's surveys starting in 2016. A change in sampling method can affect the comparison between surveys.

In a study published in 2017, based on a medical records database of 351,799 health fund (HMO) members aged 20 to 70, an asthma diagnosis was found in 5.68%. This is a different measure from a self-report survey, and it depends on what is recorded in the medical file and on the population included in the study.

A third measure comes from the National Program for Quality Indicators in Community Healthcare. It does not count everyone with asthma, but rather the age group included in the persistent asthma indicator, based on asthma medication purchase criteria and, in some inclusion pathways, also diagnoses recorded at doctor visits. In 2023, the prevalence according to this indicator was 0.8%.

These three measures do not describe the same population: one is based on reports by people whom a doctor diagnosed at some point, one on a diagnosis recorded in a medical record, and one on a working definition of persistent asthma in a quality indicator. The age groups and criteria are also different. So they cannot be combined into a range, and one cannot be subtracted from another to determine how many people are undiagnosed or untreated.

“You cannot subtract a survey figure from a quality-indicator figure and get an answer about who is undiagnosed or untreated.”

What Can We Learn from the Gap Between Diagnosis and Treatment?

In the national health survey, among those who reported that a doctor had diagnosed them with asthma at some point, 39.0% of men and 50.6% of women reported receiving asthma medication in the year before the survey.

This is an important figure, but it needs to be read with care. The survey does not specify which medication was received and does not prove that it was actually taken regularly. In addition, the diagnosis report refers to a diagnosis at any time, so it may also include people whose disease is in remission. It is fair to say that the figure points to a gap between reporting a past diagnosis and reporting medication in the past year, but on its own it does not prove a lack of treatment or incorrect use of medication.

The quality indicators also show the picture from a different angle. The AMR indicator checks, among those included in the persistent asthma indicator, whether the number of asthma controller medication packs was at least half of all asthma medication packs purchased. In 2023, this rate was 77.6%. In other words, for about 22.4% of those included in the indicator, controller medication packs made up less than half of all asthma medication packs purchased.

The same report also found that the flu vaccination rate among people with persistent asthma included in the indicator fell from 42.3% in 2020 to 24.1% in 2023. This figure is a good reason for a short conversation with your family doctor before winter.

Who Is Asthma More Common In, and When Does the Picture Change?

Until adolescence, asthma is more common in boys. Later in life, the picture changes. According to Israel's national health survey, among men aged 21 and over, the highest rate of reporting a doctor's diagnosis at some point was in the 35 to 44 age group, at 12.0%. In the 55 to 64 age group the rate was 5.2%, and among those 65 and over, 8.1%.

For women, the curve is different: 6.4% at ages 21 to 34, 6.1% at ages 35 to 44, and a gradual rise to 10.2% at age 65 and over. According to the survey table, the reversal between women and men appears from age 55 onward, when the rate of reporting an asthma diagnosis at some point is higher among women.

Does asthma "go away with age"? Sometimes, but not for everyone. In a large Israeli study, among 17-year-olds with past or current asthma who were included in the study, 22.4% of boys and 9.1% of girls were defined as being in remission. In this study, remission was not determined by self-report alone: the definition also included three years without symptoms and without asthma medication, together with normal results on a physical exam, spirometry and a challenge test. Even so, this is a research definition at age 17, and not a promise that the asthma will not come back later in life.

In practical terms, childhood asthma can weaken or go into remission, but you cannot assume it will simply disappear. If there were symptoms in the past, and if they come back later in life, it is worth telling your doctor about this history.

Asthma That Starts in Adulthood Is Not Rare

In a Finnish study of 8,199 respondents aged 20 to 69, 842 reported an asthma diagnosis. Of these, 59.3% reported being first diagnosed at age 18 or older. This shows that a diagnosis in adulthood is not unusual.

In another Finnish study from 2020, asthma was classified as allergic based on reports of allergic rhinitis diagnosed by a doctor. This rate was about 70% among those diagnosed with asthma at ages 0 to 9, about 38% among those diagnosed at ages 40 to 49, and about 19% at ages 50 to 59. So when asthma is diagnosed in adulthood, it is usually non-allergic.

Separately from the split into allergic and non-allergic asthma, it is important to look into exposures at work. GINA estimates that 5% to 20% of new adult-onset asthma cases are attributed to occupational exposure, which can act through different mechanisms. A useful screening question is whether symptoms improve on weekends or holidays and return when you go back to work.

“An asthma diagnosis later in life is not strange. It just changes the questions worth asking during the assessment.”

How Many Cases Are Considered Severe?

The term "severe asthma" does not describe everyone who finds their asthma hard to live with. According to GINA, a distinction is first made between difficult-to-treat asthma and asthma that is severe in degree. Severe asthma is asthma that stays uncontrolled despite good adherence to optimal treatment with a high-dose inhaled steroid together with a long-acting bronchodilator, and after treating contributing factors (comorbidities), or asthma that gets worse when the high-dose treatment is reduced. Before making this determination, inhaler technique, regular use, exposures and other conditions are also checked.

In GINA's 2026 chart, based on a Dutch study published in 2015, estimates show about 17% of adults with asthma as having difficult-to-treat asthma, and about 3.7% as having severe asthma.

In an Israeli records study published in 2017, among health fund (HMO) members diagnosed with asthma, 4.65% met the definition of severe asthma according to the definitions used in the study. Of this group, about a third were classified as uncontrolled.

When Do the Numbers Call for a Talk with Your Doctor?

Most of the numbers in this article are population data. They are not a personal forecast. But there are a few personal numbers worth bringing to your appointment with the doctor: how many flare-ups needed oral steroids in the past year, how many times you went to the emergency room or an urgent care center, and how many reliever inhalers (SABA) you used.

According to GINA, buying three or more canisters a year of SABA, a short-acting beta-2 agonist used for relief, is linked to a higher risk of flare-ups and emergency room visits. These thresholds refer to 200-dose canisters. Buying 12 or more canisters a year is linked to a higher risk of death from asthma. The thresholds do not apply to reliever inhalers that contain an inhaled steroid and formoterol. Buying an inhaler is not proof of actual use, but it is a warning sign worth raising with your doctor.

It is important not to assume that asthma with infrequent symptoms is necessarily risk-free. GINA notes that up to about 30% of flare-ups and asthma deaths occur in people whose symptoms appear only rarely: less than once a week, or only during strenuous exercise. Treatment containing an inhaled steroid reduces the risk of severe flare-ups compared with SABA treatment alone.

“Even when there are few symptoms, the risk of a severe flare-up is not necessarily low.”

Where Is the Israeli Data Encouraging?

An Israeli study that examined children's hospital admissions for asthma at ages 1 to 14, using the national hospitalization registry, found a drop in the annual age-adjusted admission rate from 2.14 per 1,000 children in 1996 to 0.89 per 1,000 children in 2017. That is a drop of about 58%.

Here too, it's important to keep things in context: the drop in hospital admissions does not mean asthma has disappeared, and it does not guarantee that any particular person won't have a flare-up. The study recorded a decline at the population level, but it did not determine how much of this decline was due to changes in treatment, diagnosis and follow-up.

What's Your Number?

National figures matter for policy, but when you meet your doctor, your personal numbers matter more. Try to come with three simple pieces of information:

  • How many flare-ups you had in the past year, and especially how many of them needed steroid tablets.
  • How many times you went to the emergency room or sought urgent care because of asthma.
  • How many reliever inhalers you bought or used up in the past year, and what your reliever inhaler contains. If it is a SABA-type inhaler, it's also worth noting how many canisters were bought.

This information helps show not only whether you have asthma, but how well controlled it is, whether your treatment is right for you, and whether your follow-up needs to change.

Questions and Answers

How many people around the world live with asthma?

The World Health Organization estimates that about 363 million people were living with asthma in 2023. The GINA 2026 report uses an estimate of about 300 million people. These are two estimates from different sources and different data periods, so it's better not to turn them into a single range.

How common is asthma in Israel?

In the 2018–2020 National Health Survey, 8.5% of people aged 21 and over reported that a doctor had diagnosed them with asthma at some point. In a medical records study published in 2017, an asthma diagnosis was found in 5.68% of health fund members aged 20 to 70. In the 2023 persistent asthma indicator, the rate was 0.8%, among the age group defined by the indicator and based on medication purchase criteria (and, in some pathways, recorded diagnoses as well). These three figures measure different things and cannot be subtracted from one another.

Is asthma a children's disease?

Not only. Asthma is common in childhood, but it can start at any age. In a Finnish study, 59.3% of adults who reported an asthma diagnosis said they were first diagnosed at age 18 or older. In another Finnish study, the proportion of asthma classified as allergic, based on reports of doctor-diagnosed allergic rhinitis, was lower in some of the older age-at-diagnosis groups.

Medical review and consultation: Dr. Merav Ben Avraham, Specialist in family medicine and pulmonology